Heart failure & cardiomyopathies
Long-Term Outcomes of Patients With Apical Hypertrophic Cardiomyopathy Utilizing a New Risk Score
Authors' conclusion
aHCM constituted 6.8% of our overall HCM cohort with a composite event rate of 2.8%/year. The aHCM risk score provided good discrimination in predicting the composite primary endpoint, with a higher score associated with a higher rate of events.
Study context
- Population
- Patients diagnosed with apical hypertrophic cardiomyopathy (aHCM)
- Participants
- 462 patients
- Outcome
- Death, appropriate defibrillator discharge, or need for cardiac transplantation (composite)
Main finding
As reported in the abstract
Composite primary endpoint · 6.3 ± 4.8 years
- Composite events
- 80 (17%)
- Death
- 62 [13%]
- aHCM risk score discrimination (C-statistic)
- 0.75
- Expected to observed ratio
- 1.02
- Calibration slope
- 0.91
Observational data: associations, not effects.
Further findings
Baseline characteristics
- Asymptomatic
- 67%
- No risk factors for SCD
- 69%
- Mean LVEF
- 64% ± 8%
- LA volume index
- 36 ± 15 ml/m²
- RV systolic pressure
- 32 ± 10 mm Hg
- Apical aneurysm
- 51(11%)
- Delayed gadolinium enhancement on CMR (246 [53%] with CMR)
- 170 (71%)
- Mean percentage of enhancement
- 4.9% ± 6.6%
Original publication
Long-Term Outcomes of Patients With Apical Hypertrophic Cardiomyopathy Utilizing a New Risk Score. JACC Adv. Published 1 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →